Anticoagulation therapy in children

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 4, 2003, Pages 425-432

  Revel Vilk, Shoshana ^b   Chan, Anthony K C ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Anticoagulants; Children; Heparin; Thromboembolism; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DALTEPARIN; DANAPAROID; ENOXAPARIN; FIBRINOGEN; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; REVIPARIN; TINZAPARIN; VON WILLEBRAND FACTOR; WARFARIN;

ADOLESCENT DISEASE; ANTICOAGULANT THERAPY; ARTERY CATHETER; BLEEDING; CENTRAL VENOUS CATHETER; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; HEMOSTASIS; HUMAN; INFANT DISEASE; NEWBORN DISEASE; PARTIAL THROMBOPLASTIN TIME; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HEPARIN; HUMANS;

EID: 0042865988     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42592     Document Type: Review

References (71)

1. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257
2. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-681
3. Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutanous cardiac catheterization in children. Circulation 1974;50:565-569
4. deVeber G, Andrew M, Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417-423
5. Schoenberg BS, Mellinger JF, Schoenberg DF. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology 1978;28:763-768
6. Broderick J, Talbot TG, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol 1993;8:250-255
7. deVeber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998;55:1539-1543
8. Andrew M, David M, deVeber G, Brooker LA. Arterial thromboembolic complications in paediatric patients. Thromb Haemost 1997;78:715-725
9. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657
10. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172
11. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992;8:1998-2005
12. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994;72:836-842
13. Schmidt B, Ofosu F, Mitchell L, Brooker L, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989;25:405-408
14. Chan AK, Berry LR, Monagle PT, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002;87:606-613
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:S64-S94
16. Vieira A, Berry L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991;63:85-98
17. Schmidt B, Buchanan MR, Ofosu F, Brooker L, Hirsh J, Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Haemost 1988;60:289-292
18. Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan MR. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988;52:517-527
19. Streif W, Mitchell LG, Andrew M. Antithrombotic therapy in children. Curr Opin Pediatr 1999;11:56-64
20. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35:78-83
21. Monagle P, Michelson AD, Bovill E, Andrew M. Antithromboric therapy in children. Chest 2001;119:S344-S370
22. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients - a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999;158(Suppl 3):S130-S133
23. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001;27:293-299
24. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002;109:E10 (Abst)
25. Deitcher SR, Topoulos AP, Bartholomew JR, Kichus-Chrisant MR. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr 2002;140:264-266
26. Nguyen TN, Gal P, Ransom JL, Carlos R. Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:229-233
27. Avioli L. Heparin induced osteoporosis: an appraisal. Adv Exp Med Biol 1975;52:375-387
28. Dix D, Andrew M, Marzinotto V, et al. The use of low-molecular-weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-445
29. Albisetti M, Andrew M. Low-molecular-weight heparin in children. Eur J Pediatr 2002;161:71-77
30. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698
31. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-318
32. Vieira A, Ofosu F, Andrew M. The activity of low-molecular-weight heparin (CY222) in neonatal plasma. Thromb Haemost 1991;63:85-98
33. Andrew M, Ofosu F, Brooker L, Buchanan M. The comparison of the pharmacokinetics of a low-molecular-weight heparin in the newborn and adult pig. Thromb Res 1989;56:529-539
34. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low-molecular-weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85-92
35. Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low-molecular-weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999;158(Suppl 3):S134-S139
36. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low-molecular-weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003;109:101-108
37. Revel-Vilk S, Sheratkumar A, Massicotte P, et al. Natural history of arterial and venous thrombosis in children treated with low-molecular-weight heparin. A longitudinal study by Doppler ultrasound. Blood 2002;100:279a (Abst)
38. Hofmann S, Knoefler R, Lorenz N, et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 2001;103:345-353
39. Crowther MA, Berry LR, Mongale PT, Chan AK. Mechanism responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178-186
40. Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990;63:271-274
41. Tait DE Does low-molecular-weight heparin cause bleeding? Thromb Haemost 1997;78:1422-1425
42. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:S8-S21
43. Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998;80:570-574
44. Andrew M, Monagle PT, Brooker L. Developmental hemostasis: relevance to thromboembolic complication in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood. Hamilton, Ontario: BC Decker; 2000:5-46
45. Andrew M, Mongale P, Brooker L. Oral anticoagulant therapy in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood. Hamilton, Ontario: BC Decker; 2000:321-356
46. Buck ML. Anticoagulation with warfarin in infants and children. Ann Pharmacother 1996;30:1316-1322
47. Andrew M, Marzinotto V, Brooker LA, et al. Oral anticoagularion therapy in pediatric patients: a prospective study. Thromb Haemost 1994;71:265-269
48. Tait RC, Ladusans EJ, el-Metall M, Patel RG, Will AM. Oral anticoagulation in paediatric patients: dose requirements and complications. Arch Dis Child 1996;74:228-231
49. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999;94:3007-3014
50. Schmidt B, Andrew M. Report of Scientific and Standardization Subcommittee on Neonatal Hemostasis Diagnosis and Treatment of Neonatal Thrombosis. Thromb Haemost 1992;67:381-382
51. Marzinotto V, Monagle P, Chan A, et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000;21:347-352
52. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-1553
53. Hooshang T, Capitanio M. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology 1990;176:728-730
54. Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long-term warfarin therapy. Thromb Haemost 1999;81(Suppl):1333a (Abst)
55. Ansell JE, Weitz JI, Comerota AJ. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology (Am Soc Hematol Educ Program) 2000;266-284
56. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 2002;28(Suppl 2):15-24
57. Markwardt F. Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Semin Thromb Hemost 2001;27:523-530
58. Prisco D, Flaciani M, Antonucci E, Gensini GE Hirudins for prophylaxis and treatment of venous thromboembolism. Semin Thromb Hemost 2001;27:543-549
59. Eriksson BI, Ekman S, Lindbratt S. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-333
60. Eriksson BI, Wille-Jørgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335
61. Schiele F, Lindgaerde F, Eriksson H, et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicenter prospective dose-ranging randomized trial. Thromb Hemost 1997;77:834-838
62. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851
63. Boshkov LK, Thomas G, Kirbi A, et al. Pharmacokinetics of argatroban infusion in a 6-month-old congenital cardiac patient with previously diagnosed heparin-induced thrombocytopenia. Blood 2002;100:278a (Abst)
64. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide. Blood 1998;91:4197-4205
65. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726
66. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995;74:1384-1385
67. Spanier TB, Chen JM, Oz MC, et al. Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998;116:860-869
68. Lee A, Agnelli G, Büller H, et al. Dose-response study of recombinant factor VIIa/tissue-factor inhibitor recombinant nematode anticoagulant protein C2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104:74-78
69. Barrington KJ. Umbilical artery catheters in the newborn: effect of catheter materials [review]. Cochrane Database Syst Rev 2000;CD000949
70. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000;26:967-972
71. Klement P, Du YJ, Berry L, Andrew M, Chan AK. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex. Biomaterials 2002;23:527-535